Safety of MF59-adjuvanted versus non-adjuvanted influenza vaccines in children and adolescents : an integrated analysis.

Black, Steven;Della Cioppa, Giovanni;Malfroot, Anne;Nacci, Pantaleo;Vertruyen, André;et.al.
(2010) Vaccine — Vol. 28, n° 45, p. 7331-7336 (2010)

Files

VaccineBlack.pdf
  • Closed Access
  • Adobe PDF
  • 150.67 KB
Request a copy
75524.pdf
  • Restricted Access
  • Adobe PDF
  • 3.49 MB
Request a copy

Details

Authors
  • Black, Steven
    Author
  • Della Cioppa, Giovanni
    Author
  • Malfroot, Anne
    Author
  • Nacci, Pantaleo
    Author
  • Sokal, EtienneUCLouvain
    Author
  • Vertruyen, André
    Author
Show more
Abstract
We reviewed the safety of MF59-adjuvanted versus non-adjuvanted influenza vaccines in children and adolescents (aged 6 months-18 years) in an integrated analysis of all pediatric trials evaluating MF59-containing influenza vaccines completed to date (5 trials). In the MF59-adjuvanted group (n=1181) versus the non-adjuvanted group (n=545) there was no increase in the incidence of unsolicited adverse events and serious adverse events. As expected, solicited local or systemic reactions occurred more frequently in MF59-adjuvanted subjects; however, a majority of reactions were mild and transient. These data support the safety of MF59-adjuvanted influenza vaccines in the pediatric population.
Affiliations

Citations

  • APA
  • Chicago
  • FWB

Black, S., Della Cioppa, G., Malfroot, A., Nacci, P., Nicolay, U., Pellegrini, M., Sokal, E., & Vertruyen, A. (2010). Safety of MF59-adjuvanted versus non-adjuvanted influenza vaccines in children and adolescents : an integrated analysis. Vaccine, 28(45), 7331-7336. https://doi.org/10.1016/j.vaccine.2010.08.075 (Original work published 2010)